参考文献/References:
[1] Cryer PE,Davis SN,Shamoon H. Hypoglycemia in diabetes[J].Diabetes Care,2003,26(6):1902-1912.
[2] Östenson CG,Geelhoed-Duijvestijn P,Lahtela J,et al.Self-reported non-severe hypoglycaemic events in Europe[J].Diabet Med,2014,31(1):92-101.DOI:10.1111/dme.12261.
[3] Frier BM.Hypoglycaemia in diabetes mellitus:epidemiology and clinical implications[J].Nat Rev Endocrinol,2014,10(12):711-722.DOI:10.1038/nrendo.2014.170.
[4] Goto A,Goto M,Terauchi Y,et al.Association between severe hypoglycemia and cardiovascular disease risk in Japanese patients with type 2 diabetes[J].J Am Heart Assoc,2016,5(3):e002875.DOI:10.1161/JAHA.115.002875.
[5] Leong A,Berkowitz SA,Triant VA,et al.Hypoglycemia in diabetes mellitus as a coronary artery disease risk factor in patients at elevated vascular risk[J].J Clin Endocrinol Metab,2016,101(2):659-668.DOI:10.1210/jc.2015-3169.
[6] Zinman B,Marso SP,Christiansen E,et al.Hypoglycemia, cardiovascular outcomes, and death: the LEADER experience[J].Diabetes Care,2018,41(8):1783-1791.DOI:10.2337/dc17-2677.
[7] Hypoglycemia in the diabetes control and complications trial. The diabetes control and complications trial research group[J].Diabetes,1997,46(2):271-286.
[8] Gruden G,Barutta F,Chaturvedi N,et al.Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes: the EURODIAB Prospective Complications Study[J].Diabetes Care,2012,35(7):1598-1604.DOI:10.2337/dc11-1531.
[9] Khunti K,Davies M,Majeed A,et al.Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study[J].Diabetes Care,2015,38(2):316-322.DOI:10.2337/dc14-0920.
[10] Lee AK,Warren B,Lee CJ,et al.The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes[J].Diabetes Care,2018,41(1):104-111.DOI:10.2337/dc17-1669.
[11] ORIGIN Trial Investigators,Mellbin LG,Rydén L,et al.Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGINtrial[J].Eur Heart J,2013,34(40):3137-3144.DOI:10.1093/eurheartj/eht332.
[12] Zoungas S, Patel A, Chalmers J,et al. Severe hypoglycemia and risks of vascular events and death[J].N Engl J Med,2010,363(15):1410-1418. DOI:10.1056/NEJMoa1003795.
[13] Bonds DE,Miller ME,Bergenstal RM,et al.The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study[J].BMJ,2010,340:b4909.DOI:10.1136/bmj.b4909.
[14] Mohebbi MR,Punj P,Chandrasekaran PN,et al.Paroxysmal sympathetic hyperactivity after symptomatic hypoglycemia[J].Neurol India,2017,65(1):189-190.DOI:10.4103/0028-3886.198187.
[15] Rehni AK,Dave KR.Impact of hypoglycemia on brain metabolism during diabetes[J].Mol Neurobiol,2018,55(12):9075-9088.DOI:10.1007/s12035-018-1044-6.
[16] Jaiswal M,McKeon K,Comment N,et al.Association between impaired cardiovascular autonomic function and hypoglycemia in patients with type 1 diabetes[J].Diabetes Care,2014,37(9):2616-2621.DOI:10.2337/dc14-0445.
[17] Frier BM,Schernthaner G,Heller SR.Hypoglycemia and cardiovascular risks[J].Diabetes Care,2011,34(Suppl 2):S132-S137.DOI:10.2337/dc11-s220.
[18] Obeyesekere MN,Antzelevitch C,Krahn AD.Management of ventricular arrhythmias in suspected channelopathies[J].Circ Arrhythm Electrophysiol,2015,8(1):221-231.DOI:10.1161/CIRCEP.114.002321.
[19] Gill GV,Woodward A,Casson IF,et al.Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes--the 'dead in bed' syndrome revisited[J].Diabetologia,2009,52(1):42-45.DOI:10.1007/s00125-008-1177-7.
[20] Al-Khatib SM,LaPointe NM,Kramer JM,et al.What clinicians should know about the QT interval[J].JAMA,2003,289(16):2120-2127.DOI:10.1001/jama.289.16.2120
[21] Mezquita-Raya P,Reyes-García R,de Torres-Sánchez A,et al. Electrical changes during hypoglycaemia in patients with type 1 and type 2 diabetes and high cardiovascular risk[J].Diabetes Res Clin Pract,2018,138:44-46.DOI:10.1016/j.diabres.2018.01.024.
[22] Giunti S,Gruden G,Fornengo P,et al.Increased QT interval dispersion predicts 15-year cardiovascular mortality in type 2 diabetic subjects: the population-based Casale Monferrato Study[J].Diabetes Care,2012,35(3):581-583.DOI:10.2337/dc11-1397.
[23] Tsujimoto T,Yamamoto-Honda R,Kajio H,et al.High risk of abnormal QT prolongation in the early morning in diabetic and non-diabetic patients with severe hypoglycemia[J].Ann Med,2015,47(3):238-244.DOI:10.3109/07853890.2015.1017528.
[24] Novodvorsky P,Bernjak A,Chow E,et al.Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes[J].Diabetes Care,2017,40(5):655-662.DOI:10.2337/dc16-2177.
[25] Chow E,Bernjak A,Walkinshaw E,et al.Cardiac autonomic regulation and repolarization during acute experimental hypoglycemia in type 2 diabetes[J].Diabetes,2017,66(5):1322-1333.DOI:10.2337/db16-1310.
[26] Joy NG,Perkins JM,Mikeladze M,et al.Comparative effects of acute hypoglycemia and hyperglycemia on pro-atherothrombotic biomarkers and endothelial function in non-diabetic humans[J].J Diabetes Complications,2016,30(7):1275-1281.DOI:10.1016/j.jdiacomp.2016.06.030.
[27] Joy NG,Tate DB,Younk LM,et al.Effects of acute and antecedent hypoglycemia on endothelial function and markers of atherothrombotic balance in healthy humans[J].Diabetes,2015,64(7):2571-2580.DOI:10.2337/db14-1729.
[28] Ratter JM,Rooijackers HM,Tack CJ,et al.Proinflammatory effects of hypoglycemia in humans with or without diabetes[J].Diabetes,2017,66(4):1052-1061.DOI:10.2337/db16-1091.
[29] Kahal H,Aburima A,Spurgeon B,et al.Platelet function following induced hypoglycaemia in type 2 diabetes[J].Diabetes Metab,2018,44(5):431-436.DOI:10.1016/j.diabet.2018.04.004.
[30] Gajos G,Konieczynska M,Zalewski J,et al.Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk[J].Cardiovasc Diabetol,2015,14:44.DOI:10.1186/s12933-015-0207-2.
[31] Marketou ME,Kintsurashvili E,Androulakis NE,et al.Blockade of platelet alpha2B-adrenergic receptors: a novel antiaggregant mechanism[J].Int J Cardiol,2013,168(3):2561-2566.DOI:10.1016/j.ijcard.2013.03.051.
相似文献/References:
[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(02):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(02):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]刘璠,张趁儒,周慧敏,等.2型糖尿病患者利拉鲁肽替代预混胰岛素治疗的有效性和安全性分析[J].国际内分泌代谢杂志,2014,(04):237.[doi:10.3760/cma.j.issn.1673-4157.2014.04.006]
Liu Fan,Zhang Chenru,Zhou Huimin,et al.Efficacy and safety of liraglutide switched from premixed insulin in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2014,(02):237.[doi:10.3760/cma.j.issn.1673-4157.2014.04.006]
[4]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(02):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[5]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制
——2014年美国糖尿病协会“杰出科学成就奖”
演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(02):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[6]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(02):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[7]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(02):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[8]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(02):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[9]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(02):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[10]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(02):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]